𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients

✍ Scribed by Jonathan Hebb; Sarit Assouline; Caroline Rousseau; Pierre DesJardins; Stephen Caplan; Merrill J. Egorin; Lilian Amrein; Raquel Aloyz; Lawrence Panasci

Book ID
105993644
Publisher
Springer
Year
2010
Tongue
English
Weight
325 KB
Volume
68
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression β‰₯ Grade 3, requiring interruption of thera